Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

ClinicalTrials.gov ID: NCT02224560

Public ClinicalTrials.gov record NCT02224560. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study was to evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo in participants with Lennox-Gastaut syndrome (LGS).

Study identification

NCT ID: NCT02224560
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Jazz Pharmaceuticals; Industry
Enrollment: 225 participants

Conditions and interventions

Conditions

Interventions

GWP42003-P Drug
Placebo control Drug

Drug

Eligibility (public fields only)

Age range: 2 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 8, 2015 (Actual)
Primary completion: May 19, 2016 (Actual)
Completion: May 19, 2016 (Actual)
Last update posted: Sep 28, 2022

2015 – 2016

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Phoenix	Arizona	85054	—
Not listed	Los Angeles	California	90027	—
Not listed	Hartford	Connecticut	06106	—
Not listed	Orlando	Florida	32819	—
Not listed	Augusta	Georgia	30912	—
Not listed	Boise	Idaho	83702	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Buffalo	New York	14222	—
Not listed	New York	New York	10003	—
Not listed	New York	New York	10016	—
Not listed	Clemmons	North Carolina	27012	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Columbus	Ohio	43205	—
Not listed	York	Pennsylvania	17403	—
Not listed	Charleston	South Carolina	29425	—
Not listed	Austin	Texas	78723	—
Not listed	Fort Worth	Texas	76104	—
Not listed	Charlottesville	Virginia	22903	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02224560, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2022 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02224560 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →